Genetic basis of heterogeneity and severity in sickle cell disease

被引:87
作者
Habara, Alawi [1 ,2 ]
Steinberg, Martin H. [2 ]
机构
[1] Univ Dammam, Dept Clin Biochem, Coll Med, Dammam 31451, Saudi Arabia
[2] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA
关键词
Severity in sickle cell disease; subphenotypes of sickle cell disease; single nucleotide polymorphisms; genome-wide association study; hemolysis; genotype-phenotype correlation; ACUTE-CHEST-SYNDROME; SERUM BILIRUBIN LEVELS; PULMONARY-HYPERTENSION; FETAL-HEMOGLOBIN; NITRIC-OXIDE; VASCULAR COMPLICATIONS; PROMOTER POLYMORPHISM; VASOOCCLUSIVE CRISIS; VARIANT ALLELES; RISK-FACTOR;
D O I
10.1177/1535370216636726
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Sickle cell disease, a common single gene disorder, has a complex pathophysiology that at its root is initiated by the polymerization of deoxy sickle hemoglobin. Sickle vasoocclusion and hemolytic anemia drive the development of disease complications. In this review, we focus on the genetic modifiers of disease heterogeneity. The phenotypic heterogeneity of disease is only partially explained by genetic variability of fetal hemoglobin gene expression and co-inheritance of a thalassemia. Given the complexity of pathophysiology, many different definitions of severity are possible complicating a full understanding of its genetic foundation. The pathophysiological complexity and the interlocking nature of the biological processes underpinning disease severity are becoming better understood. Nevertheless, useful genetic signatures of severity, regardless of how this is defined, are insufficiently developed to be used for treatment decisions and for counseling.
引用
收藏
页码:689 / 696
页数:8
相关论文
共 82 条
[1]   Association of polymorphisms of IGF1R and genes in the transforming growth factor-β bone morphogenetic protein pathway with Bacteremia in sickle cell anemia [J].
Adewoye, Adeboye H. ;
Nolan, Vikki G. ;
Ma, Qianli ;
Baldwin, Clinton ;
Wyszynski, Diego F. ;
Farrell, John J. ;
Farrer, Lindsay A. ;
Steinberg, Martin H. .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (05) :593-598
[2]   Lack of Duffy antigen expression is associated with organ damage in patients with sickle cell disease [J].
Afenyi-Annan, Araba ;
Kail, Melanie ;
Combs, Martha R. ;
Orringer, Eugene P. ;
Ashley-Koch, Allison ;
Telen, Marilyn J. .
TRANSFUSION, 2008, 48 (05) :917-924
[3]   Fetal hemoglobin in sickle cell anemia [J].
Akinsheye, Idowu ;
Alsultan, Abdulrahman ;
Solovieff, Nadia ;
Duyen Ngo ;
Baldwin, Clinton T. ;
Sebastiani, Paola ;
Chui, David H. K. ;
Steinberg, Martin H. .
BLOOD, 2011, 118 (01) :19-27
[4]   Human platelet alloantigens (HPA) 1, HPA2, HPA3, HPA4, and HPA5 polymorphisms in sickle cell anemia patients with vaso-occlusive crisis [J].
Al-Subaie, Abeer M. ;
Fawaz, Naglaa A. ;
Mahdi, Najat ;
Al-Absi, Iman K. ;
Al-Ola, Khadija ;
Ameen, Ghada ;
Almawi, Wassim Y. .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 83 (06) :579-585
[5]   Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea [J].
Almeida, Camila Bononi ;
Botelho Souza, Lucas Eduardo ;
Leonardo, Flavia Costa ;
Maranhao Costa, Fabio Trindade ;
Werneck, Claudio C. ;
Covas, Dimas Tadeu ;
Costa, Fernando Ferreira ;
Conran, Nicola .
BLOOD, 2015, 126 (06) :711-720
[6]   Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease [J].
Ashley-Koch, Allison E. ;
Elliott, Laine ;
Kail, Melanie E. ;
De Castro, Laura M. ;
Jonassaint, Jude ;
Jackson, Terry L. ;
Price, Jennifer ;
Ataga, Kenneth I. ;
Levesque, Marc C. ;
Weinberg, J. Brice ;
Orringer, Eugene P. ;
Collins, Ann ;
Vance, Jeffery M. ;
Telen, Marilyn J. .
BLOOD, 2008, 111 (12) :5721-5726
[7]   MYH9 and APOL1 are both associated with sickle cell disease nephropathy [J].
Ashley-Koch, Allison E. ;
Okocha, Emmanuel C. ;
Garrett, Melanie E. ;
Soldano, Karen ;
De Castro, Laura M. ;
Jonassaint, Jude C. ;
Orringer, Eugene P. ;
Eckman, James R. ;
Telen, Marilyn J. .
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 155 (03) :386-394
[8]   Pulmonary hypertension in patients with sickle cell disease: a longitudinal study [J].
Ataga, Kenneth I. ;
Moore, Charity G. ;
Jones, Susan ;
Olajide, Oludamilola ;
Strayhorn, Dell ;
Hinderliter, Alan ;
Orringer, Eugene P. .
BRITISH JOURNAL OF HAEMATOLOGY, 2006, 134 (01) :109-115
[9]   Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the gardos channel blocker senicapoc (ICA-17043) [J].
Ataga, Kenneth I. ;
Reid, Marvin ;
Ballas, Samir K. ;
Yasin, Zahida ;
Bigelow, Carolyn ;
St James, Luther ;
Smith, Wally R. ;
Galacteros, Frederic ;
Kutlar, Abdullah ;
Hull, James H. ;
Stocker, Jonathan W. .
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (01) :92-104
[10]   Mortality in sickle cell patients on hydroxyurea therapy [J].
Bakanay, SM ;
Dainer, E ;
Clair, B ;
Adekile, A ;
Daitch, L ;
Wells, L ;
Holley, L ;
Smith, D ;
Kutlar, A .
BLOOD, 2005, 105 (02) :545-547